Canaccord analyst William Plovanic raised the firm’s price target on Tandem Diabetes (TNDM) to $35 from $24 and keeps a Buy rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $21 from $18 at Mizuho
- Tandem Diabetes upgraded to Outperform from Neutral at Baird
- Citi ups Tandem target, adds ‘downside 90-day catalyst watch’
- Tandem Diabetes price target raised to $23 from $17 at Morgan Stanley
- Tandem Diabetes Care Appoints Sandra Beaver to Board